Sutro Biopharma Income Statement (2016-2026) | STRO

Income Statement Dec2016 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Revenue & cost
Revenue (Quarter)
28.05M8.52M10.65M5.90M28.10M25.15M8.63M12.67M10.41M16.92M113.72M13.01M25.71M8.52M14.81M17.40M63.74M9.69M6.60M9.84M
Operating items
Research & Development (Quarter)
25.31M26.60M29.93M29.99M32.33M31.71M43.13M39.40M41.59M45.67M53.77M56.88M62.02M62.11M71.04M51.60M38.33M39.85M36.64M31.70M
Selling, General & Administrative (Quarter)
12.54M16.59M15.76M15.04M15.14M14.64M14.72M15.51M15.00M15.27M16.80M12.72M12.37M14.33M9.03M13.27M10.34M8.74M8.66M7.83M
Restructuring Costs (Quarter)
4.25M13.01M7.31M1.58M0.20M
Other Operating Expenses (Quarter)
16.79M5.42M2.25M2.81M
Operating Expenses (Quarter)
37.85M43.19M45.69M45.03M47.48M46.36M57.85M54.91M56.59M60.94M70.57M69.60M74.39M76.44M80.07M85.91M67.09M58.15M49.70M39.73M
Operating Income (Quarter)
-9.80M-34.67M-35.04M-39.13M-19.38M-21.21M-49.22M-42.24M-46.18M-44.01M43.15M-56.59M-48.69M-67.92M-65.26M-68.51M-3.35M-48.46M-38.05M-29.89M
EBIT (Quarter)
-9.80M-34.67M-35.04M-39.13M-19.38M-21.21M-49.22M-42.24M-46.18M-44.01M43.15M-56.59M-48.69M-67.92M-65.26M-68.51M-3.35M-48.46M-38.05M-29.89M
Non-operating items
Interest & Investment Income (Quarter)
0.17M0.11M0.10M0.12M0.20M-2.79M7.49M-2.99M-2.92M4.55M-2.54M-2.21M-1.76M22.17M-8.04M3.19M2.52M-0.74M-0.78M1.72M
Other Non Operating Income (Quarter)
Non Operating Income (Quarter)
-1.62M0.68M19.13M-4.83M-7.45M-8.17M-8.40M-8.79M-8.64M
Net income details
EBT (Quarter)
-6.15M-30.90M-38.12M-39.11M-23.51M-19.49M-34.59M-49.66M-38.37M-47.45M46.87M-58.21M-48.01M-48.79M-70.09M-67.62M-11.52M-56.86M-46.84M-38.53M
Tax Provisions (Quarter)
2.50M0.40M0.15M1.84M15.81M0.01M2.35M-0.02M-0.09M0.00M
Profit After Tax (Quarter)
-6.15M-30.90M-38.12M-39.11M-26.01M-19.49M-34.59M-50.05M-38.52M-49.28M31.07M-58.21M-48.02M-48.79M-72.44M-75.97M-11.50M-56.86M-46.76M-38.53M
Income from Non-Controlling Interests (Quarter)
-0.04M-0.84M-0.20M0.51M0.12M-0.13M-0.00M
Income from Continuing Operations (Quarter)
-6.15M-30.90M-38.12M-39.11M-26.01M-19.49M-34.59M-50.05M-38.52M-49.28M31.06M-58.21M-48.02M-48.79M-72.44M-67.62M-11.50M-56.86M-46.76M-38.53M
Consolidated Net Income (Quarter)
-6.15M-30.90M-38.12M-39.11M-26.01M-19.49M-34.59M-50.05M-38.52M-49.28M31.06M-58.21M-48.02M-48.79M-72.44M-67.62M-11.50M-56.86M-46.76M-38.53M
Income towards Parent Company (Quarter)
-6.15M-30.90M-38.12M-39.11M-26.01M-19.49M-34.59M-50.05M-38.52M-49.28M31.06M-58.21M-48.02M-48.79M-72.44M-67.62M-11.50M-56.86M-46.76M-38.53M
Net Income towards Common Stockholders (Quarter)
-6.15M-30.90M-38.12M-39.11M-26.01M-19.49M-34.59M-50.05M-38.52M-49.28M31.06M-58.21M-48.02M-48.79M-72.44M-67.62M-11.50M-56.86M-46.76M-38.53M
Additional items
EPS (Basic) (Quarter)
-1.33-6.69-8.27-8.41-5.54-3.72-6.82-8.52-6.38-8.135.16-9.47-5.91-5.95-9.43-8.14-1.36-6.70-5.50-4.53
EPS (Diluted) (Quarter)
-1.33-6.69-8.27-8.41-5.54-3.72-6.82-8.52-6.38-8.135.16-9.47-5.91-5.95-9.43-8.14-1.36-6.70-5.50-4.53
Shares Outstanding (Quarter)
4.61M4.62M4.61M4.65M4.70M5.23M5.07M5.87M6.03M6.06M6.02M6.15M8.12M8.20M7.68M8.31M8.46M8.49M8.50M8.50M
Shares Outstanding (Diluted) (Quarter)
4.61M4.62M4.61M4.65M4.70M5.23M5.07M5.87M6.03M6.06M6.02M6.15M8.12M8.20M7.68M8.31M8.46M8.49M8.50M8.50M
Shares Outstanding (Entity) (Quarter)
4.61M4.63M4.63M4.69M4.87M5.46M5.75M6.02M6.05M6.09M6.10M6.25M8.19M8.24M8.25M8.43M8.47M8.51M8.58M16.58M
EBITDA (Quarter)
-9.80M-34.67M-35.04M-39.13M-19.38M-21.21M-49.22M-42.24M-46.18M-44.01M43.15M-56.59M-48.69M-67.92M-65.26M-68.51M-3.35M-48.46M-38.05M-29.89M
Interest Expenses (Quarter)
34.47M35.72M3.67M0.70M0.60M2.79M0.43M1.70M40.56M0.30M-4.57M2.30M8.29M8.29M0.25M2.30M22.13M19.71M-7.10M11.68M
Tax Rate (Quarter)
-10.63%-0.80%-0.39%-3.88%33.74%-0.02%-3.36%0.16%0.19%0.00%